Zacks Investment Management Maxcyte, Inc. Transaction History
Zacks Investment Management
- $11.4 Billion
- Q2 2025
A detailed history of Zacks Investment Management transactions in Maxcyte, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 11,976 shares of MXCT stock, worth $20,958. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,976Holding current value
$20,958% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MXCT
# of Institutions
121Shares Held
70.8MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY8.91MShares$15.6 Million1.1% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$14.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY7.03MShares$12.3 Million0.0% of portfolio
-
Mirabella Financial Services LLP London, X06.6MShares$11.6 Million1.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$9.8 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $178M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...